Quick Answer
Indivior Pharmaceuticals, Inc. reported Total Revenue of $1.24 billion for fiscal year 2025.
Indivior Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $1.24B +4.3% |
$1.19B +8.7% |
$1.09B +21.3% |
$901.00M | — |
| Revenue (ASC 606) | $1.24B +4.3% |
$1.19B +8.7% |
$1.09B +21.3% |
$901.00M | — |
| Net Income | $210.00M +2900.0% |
$7.00M +105.6% |
-$126.00M -186.4% |
-$44.00M | — |
| Diluted EPS | $1.64 +3180.0% |
$0.05 +105.4% |
-$0.92 -187.5% |
-$0.32 | — |
| Total Assets | $1.20B -8.7% |
$1.32B -25.1% |
$1.76B -0.6% |
$1.77B -3.4% |
$1.83B |
| Cash and Equivalents | $195.00M -38.9% |
$319.00M +0.9% |
$316.00M | — | — |
| Long-Term Debt | $290.00M -7.9% |
$315.00M +32.9% |
$237.00M | — | — |
| Stockholders Equity | -$98.00M +70.9% |
-$337.00M -83.2% |
-$184.00M -1126.7% |
-$15.00M -112.4% |
$121.00M |
| R&D Expense | — | — | $106.00M +47.2% |
$72.00M +38.5% |
$52.00M |
| Operating Income | $262.00M +589.5% |
$38.00M +125.0% |
-$152.00M -87.7% |
-$81.00M | — |
| Gross Profit | $994.00M +3.9% |
$957.00M +4.1% |
$919.00M +22.7% |
$749.00M +12.8% |
$664.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $314.00M | +2.3% | +4.0% |
| Revenue (ASC 606) | September 30, 2025 | $314.00M | +2.3% | +4.0% |
| Net Income | September 30, 2025 | $42.00M | +90.9% | +133.3% |
| Diluted EPS | September 30, 2025 | $0.33 | +106.2% | +135.7% |
| Total Assets | September 30, 2025 | $1.42B | — | -2.5% |
| Cash and Equivalents | September 30, 2025 | $445.00M | — | -12.7% |
| Long-Term Debt | September 30, 2025 | $304.00M | — | -1.3% |
| Stockholders Equity | September 30, 2025 | -$207.00M | +33.2% | +19.5% |
| Operating Income | September 30, 2025 | $43.00M | +22.9% | -40.3% |
| Gross Profit | September 30, 2025 | $230.00M | -4.6% | -8.0% |
- Indivior Pharmaceuticals, Inc. reported Total Revenue of $1.24 billion for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +4.3% in Total Revenue compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Revenue (ASC 606) of $1.24 billion for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Net Income of $210.00 million for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +2900.0% in Net Income compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Diluted EPS of $1.64 per share for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +3180.0% in Diluted EPS compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Total Assets of $1.20 billion for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed a decrease of -8.7% in Total Assets compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Cash and Equivalents of $195.00 million for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed a decrease of -38.9% in Cash and Equivalents compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Long-Term Debt of $290.00 million for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed a decrease of -7.9% in Long-Term Debt compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Stockholders Equity of -$98.00 million for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +70.9% in Stockholders Equity compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported R&D Expense of $106.00 million for fiscal year 2023.
- Indivior Pharmaceuticals, Inc. showed an increase of +47.2% in R&D Expense compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Operating Income of $262.00 million for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +589.5% in Operating Income compared to the prior fiscal year.
- Indivior Pharmaceuticals, Inc. reported Gross Profit of $994.00 million for fiscal year 2025.
- Indivior Pharmaceuticals, Inc. showed an increase of +3.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: